Pfizer Inc. and partner BioNTech SE said their Covid-19 vaccine was found to be safe and generated a strong immune response in children aged 5 to 11 years in a late-stage study, bringing the prospect of broader vaccination coverage closer.
Pfizer said it would share the results with regulators in the U.S. and other countries and seek emergency use authorization in the U.S. as soon as possible.
